GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
09 Outubro 2023 - 10:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that the
U.S. Patent and Trademark Office has issued a Notice of Allowance
for Patent Application No. 17/584,231 titled “Replication-Deficient
Modified Vaccinia Ankara (MVA) Expressing Marburg Virus
Glycoprotein (GP) and Matrix Protein (VP40).” The allowed claims
generally cover GeoVax’s vector platform for expressing Marburg
virus antigens in virus-like particles (VLPs) utilizing an MVA
viral vector.
A recent presentation of data from nonhuman primate studies
demonstrated that immunization with GeoVax’s vaccine candidate,
GEO-MM01, conferred 80% survival in cynomolgus macaques following a
lethal dose of Marburg virus. Vaccination protected from viremia,
weight loss and death following challenge with a lethal Marburg
virus dose. Evaluation of immune responses following vaccination
demonstrated the presence of both neutralizing antibodies and
functional T cells, indicating a breadth of responses that combine
for optimal protection. GeoVax is currently evaluating study
designs to assess the potential for administering different dose
levels of the vaccine and different routes of vaccine delivery to
optimize utility and efficacy.
David Dodd, GeoVax President and CEO, commented, “While our
focus and development priorities continue to be our next-generation
COVID-19 vaccine and cancer immunotherapy programs, developing
vaccines against lethal hemorrhagic fever viruses represents our
commitment to addressing highly fatal endemic threats throughout
the world. Our team is committed to supporting the successful
advancement of such a vaccine, as we recognize the critically
important medical and biodefense need, reflected by the inclusion
of Marburg virus in the FDA Priority Review Voucher program. This
patent allowance adds to our growing portfolio of wholly owned,
co-owned, and in-licensed intellectual property, now standing at
over 115 granted or pending patent applications spread over 24
patent families.”
About Marburg Virus
Marburg virus (MARV) is a hemorrhagic fever virus of the
Filoviridae family, which also includes Ebola virus, and causes
severe human disease with up to a 90% fatality rate. The Marburg
virus is transmitted to people from fruit bats, and human-to-human
transmission occurs through direct contact with bodily fluids, or
contaminated surfaces and materials. MARV is rated by the World
Health Organization (WHO) as a Risk Group 4 Pathogen. In the United
States, the NIH/National Institute of Allergy and Infectious
Diseases ranks it as a Category A Priority Pathogen and the Centers
for Disease Control and Prevention lists it as a Category A
Bioterrorism Agent. MARV typically appears in sporadic outbreaks
throughout Africa and the virus continues to pose potential public
health and biodefense threats. There are currently no licensed
vaccines or therapeutics against the diseases caused by MARV.
About the GV-MVA-VLPTM
Platform
GeoVax’s GV-MVA-VLPTM vaccine platform utilizes modified
vaccinia Ankara (MVA), a large virus capable of carrying several
vaccine antigens, that expresses proteins that assemble into
virus-like particles (VLP) immunogens in the person receiving the
vaccine. The production of VLPs in the person being vaccinated can
mimic the virus production that occurs in a natural infection,
stimulating both the humoral and cellular arms of the immune system
to recognize, prevent, and control the target infection. The
MVA-VLP derived vaccines can elicit durable immune responses in the
host similar to a live-attenuated virus, while providing the safety
characteristics of a replication-defective vector.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Company Contact:info@geovax.com678-384-7220
Investor Relations
Contact:paige.kelly@sternir.com212-698-8699
Media
Contact:sr@roberts-communications.com202-779-0929
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024